AU2021222360A1 - CXCL8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue - Google Patents

CXCL8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue Download PDF

Info

Publication number
AU2021222360A1
AU2021222360A1 AU2021222360A AU2021222360A AU2021222360A1 AU 2021222360 A1 AU2021222360 A1 AU 2021222360A1 AU 2021222360 A AU2021222360 A AU 2021222360A AU 2021222360 A AU2021222360 A AU 2021222360A AU 2021222360 A1 AU2021222360 A1 AU 2021222360A1
Authority
AU
Australia
Prior art keywords
cxcl8
inhibitor
cancer
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021222360A
Other languages
English (en)
Inventor
Marcello Allegretti
Pieradelchi RUFFINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2021222360A1 publication Critical patent/AU2021222360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021222360A 2020-02-21 2021-02-19 CXCL8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue Abandoned AU2021222360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158787.0 2020-02-21
EP20158787.0A EP3868369A1 (en) 2020-02-21 2020-02-21 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
PCT/EP2021/054231 WO2021165510A1 (en) 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Publications (1)

Publication Number Publication Date
AU2021222360A1 true AU2021222360A1 (en) 2022-09-01

Family

ID=69723868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021222360A Abandoned AU2021222360A1 (en) 2020-02-21 2021-02-19 CXCL8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Country Status (7)

Country Link
US (1) US20230090111A1 (https=)
EP (2) EP3868369A1 (https=)
JP (1) JP2023519491A (https=)
AU (1) AU2021222360A1 (https=)
CA (1) CA3166653A1 (https=)
IL (1) IL294722A (https=)
WO (1) WO2021165510A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2021165510A1 (en) 2021-08-26
JP2023519491A (ja) 2023-05-11
IL294722A (en) 2022-09-01
US20230090111A1 (en) 2023-03-23
CA3166653A1 (en) 2021-08-26
EP4106739A1 (en) 2022-12-28
EP3868369A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
EA014055B1 (ru) Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP7590351B2 (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
WO2023093663A1 (en) Pharmaceutical composition and use thereof
US20090281105A1 (en) Radiotherapy enhancer
RU2832833C1 (ru) Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком
AU2021222360A1 (en) CXCL8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
US20230038138A1 (en) Combination therapy for treating cancer
JP2003277265A (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
WO2024061203A1 (en) Pharmaceutical composition and use thereof
CA2672716A1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
US10857113B2 (en) Bezafibrate for the treatment of cancer
JP5830983B2 (ja) 抗癌剤の副作用軽減剤
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
US8410096B2 (en) Antitumor agent, kit and method of treating cancer
US20250319068A1 (en) Treatment of diseases via administration of buntanetap and an antihypertensive agent
WO2025166944A1 (en) Methods of treatment using an ezh2 modulator
WO2025248485A1 (en) Pharmaceutical compositions and methods of use thereof
WO2024023766A1 (en) P13k inhibitor combination therapy
CN121941509A (zh) 用于治疗恶性肿瘤的RXRα调节剂
HK40116611A (zh) 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
JP2023511072A (ja) 癌の治療のための組み合わせおよびその用途
US20060258736A1 (en) Dosing regimen
HK40067831A (en) Methods of treating cancer using prmt5 inhibitors
FR2978662A1 (fr) Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application